News and Analysis
Nature Reviews Drug Discovery 3, 385-386 (May 2004) | doi:10.1038/nrd1387
Fresh from the Pipeline: Atomoxetine hydrochloride
Melissa Garland1 & Peter Kirkpatrick2
Top of page
Abstract
In November 2002, atomoxetine hydrochloride (Strattera; Eli Lilly), a noradrenaline-reuptake inhibitor, was approved by the US FDA for the treatment of attention-deficit–hyperactivity disorder. As the first non-stimulant drug for this common but controversial condition, and also the first approved for the treatment of adults, what influence has it had on the market since its introduction?
Author affiliations
- Melissa Garland is at Decision Resources Inc., 260 Charles Street, Waltham, Massachusetts 02453, USA.
- Peter Kirkpatrick is at Nature Reviews Drug Discovery.
Correspondence to: Melissa Garland1 Email: mgarland@dresources.com
